What’s that?

The majority of patients receiving cisplatin develop hearing loss, and a recently reported Nature study was determined to figure out why. The authors used mass spectrometry to analyze the pharmacokinetics in the cochlea. As opposed to a few days in other organs, cisplatin took up shop in the cochlea for years. We also hear (because we’re cisplatin naive) that it was particularly fond of the stria vascularis, potentially a future target for therapeutic intervention.